King Pharmaceuticals KG Investment management and advisory fees
Investment management and advisory fees at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FeeIncome.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's investment management and advisory fees.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's investment management and advisory fees?
- King Pharmaceuticals (KG) reported investment management and advisory fees of $3.12M in Q1 2026.
- How has King Pharmaceuticals's investment management and advisory fees changed year-over-year?
- King Pharmaceuticals's investment management and advisory fees increased by 286.6% year-over-year, from $807K to $3.12M.
- What does investment management and advisory fees mean?
- Revenue generated from services provided to clients, such as investment management, advisory, or administrative support. This income stream is typically non-underwriting in nature and provides diversification to the company's core insurance revenue. It reflects the company's ability to monetize its expertise and service infrastructure.